NZ596162A - Pharmaceutical composition for the treatment of heart diseases - Google Patents

Pharmaceutical composition for the treatment of heart diseases

Info

Publication number
NZ596162A
NZ596162A NZ596162A NZ59616210A NZ596162A NZ 596162 A NZ596162 A NZ 596162A NZ 596162 A NZ596162 A NZ 596162A NZ 59616210 A NZ59616210 A NZ 59616210A NZ 596162 A NZ596162 A NZ 596162A
Authority
NZ
New Zealand
Prior art keywords
treatment
pharmaceutical composition
fog2
fog1
mesp1
Prior art date
Application number
NZ596162A
Other languages
English (en)
Inventor
Vinciane Gaussin
Roland Gordon-Beresford
Christian Homsy
Original Assignee
Cardio3 Biosciences Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardio3 Biosciences Sa filed Critical Cardio3 Biosciences Sa
Priority to NZ623454A priority Critical patent/NZ623454A/en
Publication of NZ596162A publication Critical patent/NZ596162A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1406—Septums, pierceable membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1412—Containers with closing means, e.g. caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ596162A 2009-05-20 2010-05-20 Pharmaceutical composition for the treatment of heart diseases NZ596162A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ623454A NZ623454A (en) 2009-05-20 2010-05-20 Pharmaceutical composition for the treatment of heart diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2009056197 2009-05-20
PCT/EP2010/057004 WO2010133686A1 (en) 2009-05-20 2010-05-20 Parmaceutical composition for the treatment of heart diseases.

Publications (1)

Publication Number Publication Date
NZ596162A true NZ596162A (en) 2014-06-27

Family

ID=41323568

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ596162A NZ596162A (en) 2009-05-20 2010-05-20 Pharmaceutical composition for the treatment of heart diseases
NZ623454A NZ623454A (en) 2009-05-20 2010-05-20 Pharmaceutical composition for the treatment of heart diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ623454A NZ623454A (en) 2009-05-20 2010-05-20 Pharmaceutical composition for the treatment of heart diseases

Country Status (15)

Country Link
US (2) US9446076B2 (enExample)
JP (1) JP6029468B2 (enExample)
KR (1) KR101689415B1 (enExample)
CN (2) CN107028980A (enExample)
AU (1) AU2010251151B2 (enExample)
BR (1) BRPI1012116A2 (enExample)
CA (1) CA2762584A1 (enExample)
ES (1) ES2541212T3 (enExample)
IL (1) IL216399A0 (enExample)
MX (1) MX2011012183A (enExample)
NZ (2) NZ596162A (enExample)
RU (1) RU2595801C2 (enExample)
SG (1) SG175880A1 (enExample)
TW (1) TWI492707B (enExample)
WO (1) WO2010133686A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2532909T3 (es) 2004-07-30 2015-04-01 Mayo Foundation For Medical Education And Research Tratamiento de tejido cardiovascular
US9765298B2 (en) 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
WO2009145761A1 (en) * 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
US20120321595A1 (en) * 2009-11-09 2012-12-20 The Brigham And Women's Hospital, Inc. Treatment of heart disease
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
WO2013007284A1 (en) * 2011-07-08 2013-01-17 Mikael Sigvardsson A method for enriching mesenchymal stem cells and applications thereof
CN104822384A (zh) * 2012-03-30 2015-08-05 南加州大学 用于间充质干细胞诱导的免疫调节的组合物和治疗方法
JP6133402B2 (ja) * 2012-04-25 2017-05-24 ゲネラ・イストラジヴァンジャ・ディーオーオー 急性心筋梗塞を処置および診断するための方法および組成物
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
SG11201510045TA (en) * 2013-06-28 2016-01-28 Otsuka Pharma Co Ltd Trehalose and dextran-containing solution for transplanting mammalian cells
CN103667440A (zh) * 2013-09-05 2014-03-26 谢小冬 Gata4基因snp位点的用途
CN104922155A (zh) * 2014-03-18 2015-09-23 中山大学孙逸仙纪念医院 治疗心脏疾病的细胞输送方法
EP3149156B1 (en) 2014-05-28 2021-02-17 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US10363278B2 (en) 2014-06-15 2019-07-30 Amnio Technology Llc Frozen therapeutic dose and package
JP6804438B2 (ja) 2014-10-17 2020-12-23 チルドレンズ ホスピタル メディカル センター 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法
MX2017008737A (es) 2014-12-30 2018-01-25 Cell Cure Neurosciences Ltd Poblaciones de celulas rpe y metodos para generar las mismas.
RU2017132331A (ru) 2015-03-03 2019-04-03 Реджентс Оф Зэ Юниверсити Оф Миннесота Etv2 и его применения
EP3316899A4 (en) * 2015-06-30 2019-04-03 Regents of the University of Minnesota HUMANIZED CARDIAC MUSCLE
EP3316898A4 (en) 2015-06-30 2019-02-27 Regents of the University of Minnesota HUMANIZED SKELETON MUSCLE
CN105079791A (zh) * 2015-09-18 2015-11-25 郑榆坤 一种刺激体内内源干细胞的组合物及其应用
WO2017064688A1 (en) * 2015-10-15 2017-04-20 Cells For Cells, S.P.A. Neurite regeneration therapy based on exosomes derived from menstrual stem cells
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
EP4177335A1 (en) 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
CN106474456A (zh) * 2016-10-18 2017-03-08 广州赛莱拉干细胞科技股份有限公司 一种细胞制剂及其制备方法和应用
CN106619718A (zh) * 2016-10-18 2017-05-10 广州赛莱拉干细胞科技股份有限公司 一种细胞制剂及其制备方法和应用
EP3534976A4 (en) 2016-11-04 2020-09-16 Children's Hospital Medical Center PATHOLOGICAL MODELS OF HEPATIC ORGANOIDS AND ASSOCIATED METHODS OF MANUFACTURE AND USE
CN108070645A (zh) * 2016-11-11 2018-05-25 中国科学院上海生命科学研究院 Stx-t在预防和/或治疗贫血或其相关疾病的应用
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
EP3609997A4 (en) 2017-04-14 2021-03-03 Children's Hospital Medical Center COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
DE102017116204B4 (de) 2017-07-18 2024-06-27 Universität Rostock Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration
CN109497038A (zh) * 2017-09-14 2019-03-22 青岛瑞思德生物科技有限公司 一种脂肪保存液及其制备方法
EP3694603A4 (en) 2017-10-10 2021-07-14 Children's Hospital Medical Center ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF
CN107648592B (zh) * 2017-11-13 2021-05-14 深圳市喆邦生物工程有限公司 趋化因子ccl4作为制备治疗骨折药物的应用
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
SG11202005795TA (en) * 2017-12-29 2020-07-29 Cell Cure Neurosciences Ltd Retinal pigment epithelium cell compositions
CN108244096B (zh) * 2018-01-10 2019-01-04 暨赛再生医学科技有限公司 一种长期保存过表达vegf的血管内皮祖细胞的保存液
CN108379662A (zh) * 2018-02-08 2018-08-10 深圳大图科创技术开发有限公司 一种干细胞在心脏移植模型的应用
CN108546757B (zh) * 2018-03-05 2021-09-07 上海长海医院 Zfpm2-as1在制备胃癌诊断试剂或试剂盒中的应用
KR102887406B1 (ko) 2018-07-26 2025-11-19 칠드런즈 호스피탈 메디칼 센터 간-담도-췌장 조직 및 이를 제조하는 방법
CN110812369A (zh) * 2018-08-10 2020-02-21 浙江楚沅生物科技有限公司 用于治疗组织坏死或改善心脏功能的药物
WO2020056158A1 (en) 2018-09-12 2020-03-19 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
CN112143696B (zh) * 2018-10-10 2022-06-14 浙江神雁精准医疗科技有限公司 包含干细胞活性物质组合物的试剂盒及其制备方法
CN109769799A (zh) * 2019-03-20 2019-05-21 江苏瑞思坦生物科技有限公司 一种人脂肪组织保存液及其制备方法
CN111939245B (zh) * 2019-05-16 2024-03-01 龚笑海 一种心脏治疗和保护的药物组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
US20040071665A1 (en) 2000-09-05 2004-04-15 Yong-Fu Xiao Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
US6921633B2 (en) * 2002-11-18 2005-07-26 Biolife Solutions Incorporated Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
KR100674783B1 (ko) * 2003-12-09 2007-01-25 (주)안트로젠 세포 이식을 위한 세포의 생산 방법
ES2532909T3 (es) 2004-07-30 2015-04-01 Mayo Foundation For Medical Education And Research Tratamiento de tejido cardiovascular
WO2006080434A1 (ja) 2005-01-27 2006-08-03 Japan Health Sciences Foundation 間葉系幹細胞を含む細胞シート
EP1865992A2 (en) * 2005-03-31 2007-12-19 Mytogen Inc. Treatment for heart disease
WO2007033051A2 (en) * 2005-09-12 2007-03-22 Genzyme Corporation Thermally insulated transport container for cell-based products and related methods
US9765298B2 (en) * 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
NZ578728A (en) 2007-01-09 2012-01-12 Lead Pharma Cel Models Ip B V Provision of new cardiomyocyte progenitor cells and cardiomyocytes derived therefrom
WO2008109839A1 (en) * 2007-03-07 2008-09-12 Mayo Foundation For Medical Education And Research Cardiac-specific progenitor cells
KR20080103637A (ko) 2007-05-25 2008-11-28 주식회사 알앤엘바이오 지방유래 줄기세포를 함유하는 사지말단부 허혈성 질환의세포치료용 조성물
FR2917381B1 (fr) 2007-06-15 2009-10-16 Ceva Sante Animale Sa Conditionnement plastique multicouche pour la conservation d'une composition pharmaceutique
KR101828421B1 (ko) * 2007-12-04 2018-02-12 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절
EP2100954A1 (en) * 2008-03-10 2009-09-16 Assistance Publique - Hopitaux de Paris Method for generating primate cardiac progenitor cells for clinical use from primate embryonic stem cells, and their applications
EP2271209B1 (en) * 2008-03-27 2016-07-13 Biolife Solutions, Inc. Materials and methods for hypothermic collection of whole blood
WO2009145761A1 (en) 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
BE1018733A3 (fr) 2009-04-29 2011-07-05 Cardio3 Biosciences Sa Dispositif pour la delivrance d'un agent therapeutique.

Also Published As

Publication number Publication date
KR101689415B1 (ko) 2016-12-23
HK1163500A1 (en) 2012-09-14
AU2010251151B2 (en) 2015-08-20
CA2762584A1 (en) 2010-11-25
WO2010133686A1 (en) 2010-11-25
US10086016B2 (en) 2018-10-02
WO2010133686A8 (en) 2012-03-08
JP6029468B2 (ja) 2016-11-24
BRPI1012116A2 (pt) 2016-03-15
JP2012527432A (ja) 2012-11-08
TW201108935A (en) 2011-03-16
CN107028980A (zh) 2017-08-11
RU2595801C2 (ru) 2016-08-27
TWI492707B (zh) 2015-07-21
US9446076B2 (en) 2016-09-20
AU2010251151A1 (en) 2011-11-24
MX2011012183A (es) 2012-03-06
US20160279168A1 (en) 2016-09-29
ES2541212T3 (es) 2015-07-16
IL216399A0 (en) 2012-01-31
SG175880A1 (en) 2011-12-29
RU2011145370A (ru) 2013-06-27
US20120128638A1 (en) 2012-05-24
NZ623454A (en) 2015-12-24
CN102438636A (zh) 2012-05-02
KR20120046107A (ko) 2012-05-09

Similar Documents

Publication Publication Date Title
NZ596162A (en) Pharmaceutical composition for the treatment of heart diseases
Mungenast et al. Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells
AU2009240884A8 (en) Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
EP1731177A4 (en) BIOLOGICAL TISSUE SHEET, METHOD OF FORMATION THEREOF AND TRANSPLANTATION METHOD USING THE SHEET
IN2015DN01616A (enExample)
WO2008056368A3 (en) Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
SG10201903161XA (en) Methods for production and uses of multipotent cell populations
BR112014010776A8 (pt) neurônios dopaminérgicos (da) mesencefálicos para enxerto
WO2008013863A3 (en) Generation of adipose tissue and adipocytes
WO2011064669A3 (en) Adherent cells from placenta and use of same in disease treatment
GB2434157A (en) Platelets from stem cells
MX340185B (es) Células precursoras cd27 1 derivadas de médula ósea para reparación cardíaca.
NZ593364A (en) Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
RU2014146170A (ru) Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
WO2010082787A3 (ko) 연골줄기세포를 유효성분으로 포함하는 골질환 치료용 또는 항염증용 약제학적 조성물
WO2013056049A3 (en) Tubular prostheses
EP2593115A4 (en) Treatment of t-cell mediated immune disorders
WO2011003062A3 (en) Probiotic compositions and processes thereof
WO2014072720A3 (en) Cell differentiation
SG11201900986YA (en) Alleviation and treatment of ischemia reperfusion-induced lung injury using pluripotent stem cells
BR112013009043A2 (pt) composto, uso de um composto, e, método para tratar uma doença
Wang et al. Loganin epigenetically rescues mitochondrial complex III dysfunction via DNMT1-UQCRC1 demethylation to halt cardiac remodeling after myocardial infarction
WO2009094340A3 (en) Omentum and use thereof
RU2009143025A (ru) Способ использования стволовых клеток в тканезаместительной терапии

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 MAY 2017 BY JAMES + WELLS

Effective date: 20150127

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 MAY 2018 BY JAMES + WELLS

Effective date: 20170516

LAPS Patent lapsed